sellWeak cluster of 3
Susan Laura Smith sold $28k of YMAB
SVP & CHIEF COMMERCIAL OFFICER at Y-mAbs Therapeutics, Inc.. 1,682 shares at an average of $16.55, traded Mar 5, 2024, filed Mar 7, 2024.
Warning score
35Value
$28k
1,682 shares
Holdings after
33,918
-5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +5Trade size$28k at market
- 0Share of holdings soldSold 4.7% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-031939, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2024 | SOpen-market sale Common Stock | -1,682 | $16.55 | $28k | 33,918 | Mar 7, 2024 |
Related signals
Other insiders at Y-mAbs Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $57k 10,810 shares | -5% | |
| 33Weak | Y-mAbs Therapeutics, Inc. | Gerard Ber director | $8,664 722 shares | -31% | |
| 56Moderate | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $841k 70,000 shares | -30% | |
| 36Weak | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $396k 32,351 shares | -12% | |
| 38Weak | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $64k 3,900 shares | -2% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Vignesh Rajah SVP & CHIEF MEDICAL OFFICER | $28k 1,711 shares | -5% | |
| 50Moderate | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad Chief Business Officer | $1.0M 150,000 shares | -36% | |
| 29Weak | Y-mAbs Therapeutics, Inc. | Biotech ApS WG director | $44k 6,455 shares | +0% | |
| 29Weak | Y-mAbs Therapeutics, Inc. | Johan Wedell-Wedellsborg director | $44k 6,455 shares | +0% | |
| 51Moderate | Y-mAbs Therapeutics, Inc. | Biotech ApS WG director | $890k 127,549 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.